Company Overview and News
PTC Inc. (PTC - Free Report) is set to report third-quarter fiscal 2018 results on Jul 18. In the last reported quarter, the company’s adjusted earnings of 34 cents per share surpassed the Zacks Consensus Estimate by three cents. Notably, PTC has beaten the Zacks Consensus Estimate in three of the trailing four quarters, with a positive average earnings surprise of 1.23%. Notably, PTC’s top line also outpaced the consensus mark in three of the trailing four quarters.
PTC NTRS GTT NTRSP TWTR MSFT NTAP
Ansys (NASDAQ:ANSS) moved up by nearly 4% after an upgrade from Goldman Sachs Group Inc (NYSE:GS). The Canonsburg, Pennsylvania-based engineering simulation software company was upgraded on improving productivity and profits. However, after massive amounts of growth over the last 18 months, this upgrade is too late to benefit new Ansys stock investors.
JBK GS.PRICL GSC TFG GS.PRB ANSS GS.PRA GOOG GSJ GS.PRJ PTC GS GS.PRI GLSSP GOOGL GS.PRD GS.PRC MSFT ADSK GJS GS.PRN GS.PRK
In a bid to provide the most comprehensive and flexible Internet of Things (IoT) offerings in the industrial space, Rockwell Automation, Inc. (ROK - Free Report) has entered into a definitive agreement for a strategic partnership with PTC Inc. (PTC - Free Report) . Per the deal, Rockwell Automation will invest $1 billion in PTC as both companies will join forces to drive growth through digital technology.
PTC PVH CATR WLL CAT UTX AAXN ROK
Last week, Microsoft (MSFT - Free Report) announced that it was buying GitHub, checking the feasibility of an underwater data center and exciting new stuff at the electronic entertainment expo. Here are the details-
PTC WTR CTXS MSFT SNE UTX AZPN ULTI CDNS
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DUAVF DASTF PTC AM SAP DASTY SAPGF DSY BOE ADSK BA
Shares of Union Pacific Corporation (UNP - Free Report) hit a 52-week high of $144.45 during the trading session on May 18 before retracing a bit to close at $143.80. Notably, the stock has performed impressively in the past year with a surge of 33.4%, comfortably outperforming the industry’s 23.3% rally.
GATX EXPD PTC UNP SKYW GMTA GMT
Shares of Symantec Corporation (SYMC - Free Report) recovered part of last Friday’s losses, yesterday, after the company announced a conference call to discuss the ongoing investigation, post market close, which investors believe, will throw light on its internal probe. It should be noted that the company, during the fourth-quarter 2018 earnings conference call, had announced that its board’s audit committee is making an internal investigation into concerns voiced by an ex-employee.
SYMC PTC CTXS CDNS
Synaptics Incorporated (SYNA - Free Report) delivered third-quarter fiscal 2018 non-GAAP earnings of 92 centsper share that beat the Zacks Consensus Estimate by a couple of cents. The figure also surpassed the mid-point of management’s guided range of 80 cents to $1 per share. However, the figure declined 27.6% from the year-ago quarter.
MRVL PTC SYNA 9437 CTXS NTDMF NTAP DCM
Shares of Pure Storage, Inc (PSTG - Free Report) rallied to a new 52-week high of $23.19 on May 10, closing marginally lower at $23.13. The company has a market capital of $4.84 billion.
PTC PSTG CTXS NTAP
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to PTC / PTC Inc. on message board site Silicon Investor.
as of ET